| 词条 | Carotuximab |
| 释义 |
| type = mab | image = | alt = | mab_type = | source = xi/o | target = endoglin | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_UK = | legal_US = | legal_UN = | legal_NZ = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action= | excretion = | CAS_number = 1268714-50-6 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank = | C = 6420 | H = 9922 | N = 1718 | O = 2010 | S = 46 | molecular_weight = 144.8 g/mol | UNII = YB2EWE6139 | KEGG = D11260 | synonyms = TRC-105 | ChemSpiderID = none }} Carotuximab (INN[1]) (TRC-105) is a chimeric monoclonal antibody designed for the treatment of cancer. This drug was developed by Tracon Pharmaceuticals Inc.[2] It is at Phase III trials for angiosarcoma. References1. ^{{cite journal | author = World Health Organization | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114 | journal = WHO Drug Information | volume = 29 | issue = 4 | year = 2015 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL114.pdf | format=PDF}} {{Monoclonal-antibody-stub}}{{Monoclonals for tumors}}2. ^[https://searchusan.ama-assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Fcarotuximab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Carotuximab], American Medical Association. 1 : Monoclonal antibodies |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。